[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520488":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":10,"locations":31,"responsibleParty":77,"collaborators":79,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":10,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":10,"overallStatus":99,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"Adult patients referred for oesophago-gastro-duodenoscopy (OGD) to investigate any of the following symptoms: difficulty swallowing, vomiting, reflux, anaemia, gastrointestinal (GI) bleeding, upper abdominal pain and weight loss.",[13],"Other: No intervention sample collection only",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","Adult patients with known BO who are undergoing OGD for surveillance",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3","Adult patients who have been diagnosed with OGc (Ac or SCc) and are having further investigations as part of the disease staging process such as a staging laparoscopy or further OGD",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Group 4","Adult patients with OGc (Ac or SCc) who are having surgical resection of the cancer",[13],[27],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"No intervention sample collection only","No intervention",[9,15,19,23],[32,44,61],{"facility":33,"status":10,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"Royal Surrey County Hospital","Guildford","GU27WG","United Kingdom","UK",{"type":39,"coordinates":40},"Point",[41,42],-0.57427,51.23536,{"lat":42,"lon":41},{"facility":45,"status":10,"city":46,"state":10,"zip":47,"country":36,"countryCode":37,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"St Georges University Hospital","London","SW17 0QT",{"type":39,"coordinates":49},[50,51],-0.12574,51.50853,{"lat":51,"lon":50},[54,58],{"name":55,"role":56,"phone":10,"phoneExt":10,"email":57},"Subhir Bedi","CONTACT","researchgovernance@sgul.ac.uk",{"name":59,"role":60,"phone":10,"phoneExt":10,"email":10},"Chris Groves","PRINCIPAL_INVESTIGATOR",{"facility":62,"status":10,"city":46,"state":10,"zip":63,"country":36,"countryCode":37,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"The Royal Marsden NHS Foundation Trust","SW36JJ",{"type":39,"coordinates":65},[50,51],{"lat":51,"lon":50},[68,72,74],{"name":69,"role":56,"phone":70,"phoneExt":10,"email":71},"Mark Brandon-Grove","02031865416","Mark.Brandon-Grove@rmh.nhs.uk",{"name":73,"role":60,"phone":10,"phoneExt":10,"email":10},"Sacheen Kumar",{"name":75,"role":76,"phone":10,"phoneExt":10,"email":10},"Nikhil Patel","SUB_INVESTIGATOR",{"type":78,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[80],{"name":81,"class":6},"Imperial College London","100520488","imac---immune-pathways-in-oesophagogastric-cancer-100520488",false,"NCT06057220","IMaC - Immune Pathways in Oesophagogastric Cancer","Investigation of Immune Pathways and Microbiome Disruption as Drivers of Mutagenesis in Oesophagogastric Cancer","IMaC","Inclusion Criteria:\n\n1. Adult patients \\>16 years old\n2. Referred for oesophago-gastro-duodenoscopy (OGD) to investigate any of the following;\n\n   1. Symptoms including difficulty swallowing, vomiting, reflux symptoms including heartburn, anaemia, GI bleeding, upper abdominal pain and weight loss.\n   2. Oesophagitis, gastritis or GORD.\n   3. Barrett's oesophagus (BO) requiring surveillance or endoscopic therapy.\n3. Histologically confirmed OGc undergoing further investigation as part of staging such as laparoscopy and OGD or undergoing surgical resection (oesophagectomy\u002Fgastrectomy) as part of their treatment.\n\nExclusion Criteria:\n\n1. Cancers other than adenocarcinoma or squamous cell carcinoma, including but not limited to gastro-intestinal stromal tumours (GIST), mucosa associated lymphoid tissue lymphoma (MALT lymphoma) and carcinoid tumours.\n2. Patients with recurrent OGc.","ALL","17 Years",{"count":93,"type":94},310,"ESTIMATED","OBSERVATIONAL","The number of cases of oesophagogastric cancer is increasing every year. Currently, only 39% of patients with oesophageal cancer can have potentially curative treatment by the time they are diagnosed. This is because it typically presents late, and it is only when patients start to develop symptoms of advanced disease such as difficulty swallowing and weight loss, that they seek medical attention.\n\nThere are approximately 9300 new cases of oesophageal cancer in the UK each year and at 17%, it has the 5th poorest 5-year survival of all cancers in the UK.\n\nIt is diagnosed by carrying out a camera test called a gastroscopy which allows a biopsy of the cancer to be taken. This is an invasive procedure, and unlike for other types of cancer, such as bowel cancer, there is no test to risk-stratify patients at an earlier stage. Risk-stratification enables patients more likely to develop oesophagogastric cancer to be identified, which allows them to have more focused follow-up. This can potentially enable cancer to be diagnosed earlier, before the disease becomes more advanced, allowing patients to have potentially curative treatment.\n\nScientific research has identified that the healthy bacteria in the oesophagus and stomach changes as oesophagogastric cancer develops. The investigators want to see if similar changes can be identified in the healthy bacteria in the mouth which could be indicative of cancer developing in the oesophagus or stomach. The investigators then hope to use this information to develop a non-invasive risk-stratification tool that can be used to diagnose oesophagogastric cancer earlier and thereby enable more patients to be cured.",[98],"Oesophagogastric Cancer","NOT_YET_RECRUITING","2023-10-04",{"date":102,"type":103},"2023-10-05","ACTUAL",{"date":105,"type":94},"2023-10",{"date":107,"type":94},"2026-09",{"name":5,"class":6},3]